Moreover, the combination of anlotinib and a PD-1 checkpoint inhibitor can counteract the immunosuppression caused by the upregulation of PD-L1 after monotherapy, prolong the period of vessel normalization, and ultimately induce tumor regression (42). This evidence concerns the gene CD274 and neoplasm.